InnoCare Pharma's (SHA:688428, HKG:9969) net loss attributable to the parent for the first half narrowed year on year to 30.1 million yuan, or 0.02 yuan per share, from 261.8 million yuan, or 0.16 yuan per share, according to a Hong Kong bourse disclosure on Tuesday.
InnoCare's Shanghai shares dropped less than 9%, and Hong Kong shares slumped over 8% during midday trade.
The pharmaceutical company's revenue jumped 74% to 731.4 million yuan from 419.7 million yuan a year earlier, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.